Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

NCT02626884 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Interventions

DRUG: Ibrutinib

Sponsor

University of Cologne